Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

MBX Biosciences (MBX) announced positive results from its Phase 1 single ascending dose, SAD, and multiple ascending dose, MAD, clinical trial ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generall ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Discover how North Dakota is leading the way by covering Ozempic for weight loss under ACA plans, making it the first U.S.

BEHIND CLOSED DOORS: A four-hour House Democratic Caucus meeting in Springfield was so contentious that a member of Gov. JB Pritzker ’s team left in tears and the hemp legislation that was at the ...